Literature DB >> 1685962

Precocious alteration of digestive enzyme activities in small intestine and pancreas by chronic oral administration of protease inhibitor in suckling rats.

E Harada1, B Syuto.   

Abstract

1. The role of endogenous CCK in the development of digestive enzyme activities in small intestine and pancreas was investigated in suckling rats. Synthetic protease inhibitor (camostat 100 micrograms/g bwt) was orally administered twice daily for 5 days from 11 days of age. 2. Pancreatic hypertrophy and hyperplasia, and alteration of pancreatic enzyme composition, especially decreases in amylase activity and increases in trypsin and chymotrypsin activities were produced by camostat treatment. These changes were completely suppressed by simultaneous administration of the potent CCK receptor antagonist L-364,718 (1 microgram/g bwt). 3. With camostat treatment, intestinal lactase activity decreased to 41%, while maltase and sucrase activities increased 3 and 2.5 times respectively. These changes in enzyme activities were not affected by the application of L-364,718. 4. The mucosal disaccharidase and pancreatic enzyme activities could not be modified by chronic subcutaneous injection of camostat. The precocious induction of maltase and sucrase activities by camostat treatment was also observed in the adrenalectomized pups. 5. These results indicate that pancreatic growth accompanied by alteration of digestive enzyme composition in the suckling rats is regulated by endogenous CCK, but the precocious induction of disaccharidase activities is not mediated by endogenous CCK released by camostat treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685962     DOI: 10.1016/0300-9629(91)90501-3

Source DB:  PubMed          Journal:  Comp Biochem Physiol A Comp Physiol        ISSN: 0300-9629


  1 in total

1.  Pancreatic and pancreatic-like microbial proteases accelerate gut maturation in neonatal rats.

Authors:  Olena Prykhodko; Stefan G Pierzynowski; Elham Nikpey; Ester Arevalo Sureda; Olexandr Fedkiv; Björn R Weström
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.